Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Non-Current Assets (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Other Non-Current Assets readings, the most recent being $359000.0 for Q3 2025.

  • Quarterly Other Non-Current Assets rose 541.07% to $359000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $359000.0 through Sep 2025, up 541.07% year-over-year, with the annual reading at $350000.0 for FY2024, 525.0% up from the prior year.
  • Other Non-Current Assets hit $359000.0 in Q3 2025 for Terns Pharmaceuticals, up from $356000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $359000.0 in Q3 2025 and bottomed at $35000.0 in Q3 2023.
  • Average Other Non-Current Assets over 5 years is $135736.8, with a median of $64000.0 recorded in 2022.
  • The largest annual shift saw Other Non-Current Assets plummeted 72.19% in 2022 before it surged 547.27% in 2025.
  • Terns Pharmaceuticals' Other Non-Current Assets stood at $94000.0 in 2021, then plummeted by 60.64% to $37000.0 in 2022, then soared by 51.35% to $56000.0 in 2023, then surged by 525.0% to $350000.0 in 2024, then increased by 2.57% to $359000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Other Non-Current Assets are $359000.0 (Q3 2025), $356000.0 (Q2 2025), and $351000.0 (Q1 2025).